Advertisement

Journal of Neuro-Oncology

, Volume 127, Issue 1, pp 15–21 | Cite as

Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells

  • Johnathan E. Lawrence
  • Christopher J. Steele
  • Richard A. Rovin
  • Robert J. BeltonJr.
  • Robert J. Winn
Laboratory Investigation

Abstract

Extent of resection of glioblastoma (GBM) correlates with overall survival. Fluorescence-guided resection (FGR) using 5-aminolevulinic acid (5-ALA) can improve the extent of resection. Unfortunately not all patients given 5-ALA accumulate sufficient quantities of protoporphyrin IX (PpIX) for successful FGR. In this study, we investigated the effects of dexamethasone, desipramine, phenytoin, valproic acid, and levetiracetam on the production and accumulation of PpIX in U87MG cells. All of these drugs, except levetiracetam, reduce the total amount of PpIX produced by GBM cells (p < 0.05). When dexamethasone is mixed with another drug (desipramine, phenytoin, valproic acid or levetiracetam) the amount of PpIX produced is further decreased (p < 0.01). However, when cells are analyzed for PpIX cellular retention, dexamethasone accumulated significantly more PpIX than the vehicle control (p < 0.05). Cellular retention of PpIX was not different from controls in cells treated with dexamethasone plus desipramine, valproic acid or levetiracetam, but was significantly less for dexamethasone plus phenytoin (p < 0.01). These data suggest that medications given before and during surgery may interfere with PpIX accumulation in malignant cells. At this time, levetiracetam appears to be the best medication in its class (anticonvulsants) for patients undergoing 5-ALA-mediated FGR.

Keywords

Glioma 5-Aminolevulinic acid Protoporphryn IX Fluorescence-guided surgery Photodynamic therapy 

References

  1. 1.
    Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2007–2011. Neuro-oncology 16(Suppl 4):iv1–iv63. doi: 10.1093/neuonc/nou223 PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Almeida JP, Chaichana KL, Rincon-Torroella J, Quinones-Hinojosa A (2015) The value of extent of resection of glioblastomas: clinical evidence and current approach. Curr Neurol Neurosci Rep 15:517. doi: 10.1007/s11910-014-0517-x CrossRefPubMedGoogle Scholar
  3. 3.
    Schiffmann E, Shemin D (1957) Further studies on the utilization of delta-aminolevulinic acid for porphyrin synthesis. J Biol Chem 225:623–628PubMedGoogle Scholar
  4. 4.
    Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42:518–525 (discussion 525–516)CrossRefPubMedGoogle Scholar
  5. 5.
    Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. doi: 10.1016/S1470-2045(06)70665-9 CrossRefPubMedGoogle Scholar
  6. 6.
    Diez Valle R, Tejada Solis S, Idoate Gastearena MA, Garcia de Eulate R, Dominguez Echavarri P, Aristu Mendiroz J (2011) Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 102:105–113. doi: 10.1007/s11060-010-0296-4 CrossRefPubMedGoogle Scholar
  7. 7.
    Della Puppa A, De Pellegrin S, d’Avella E, Gioffre G, Rossetto M, Gerardi A, Lombardi G, Manara R, Munari M, Saladini M, Scienza R (2013) 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. Acta Neurochir 155:965–972. doi: 10.1007/s00701-013-1660-x (discussion 972)CrossRefPubMedGoogle Scholar
  8. 8.
    Schucht P, Beck J, Abu-Isa J, Andereggen L, Murek M, Seidel K, Stieglitz L, Raabe A (2012) Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 71:927–935. doi: 10.1227/NEU.0b013e31826d1e6b (discussion 935–926)CrossRefPubMedGoogle Scholar
  9. 9.
    Schucht P, Knittel S, Slotboom J, Seidel K, Murek M, Jilch A, Raabe A, Beck J (2014) 5-ALA complete resections go beyond MR contrast enhancement: shift corrected volumetric analysis of the extent of resection in surgery for glioblastoma. Acta Neurochir 156:305–312. doi: 10.1007/s00701-013-1906-7 (discussion 312)CrossRefPubMedGoogle Scholar
  10. 10.
    von Campe G, Moschopulos M, Hefti M (2012) 5-Aminolevulinic acid-induced protoporphyrin IX fluorescence as immediate intraoperative indicator to improve the safety of malignant or high-grade brain tumor diagnosis in frameless stereotactic biopsies. Acta Neurochir (Wien) 154:585–588CrossRefGoogle Scholar
  11. 11.
    Utsuki S, Oka H, Kijima C, Inukai M, Fujii K, Ishizuka M, Takahashi K, Inoue K (2012) Preoperative prediction of whether intraoperative fluorescence of protoporphyrin IX can be achieved by 5-aminolevulinic acid administration. Int J Clin Med 3:132CrossRefGoogle Scholar
  12. 12.
    Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, Hoshijima K, Priebe W, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T (2007) In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab Pharmacokinet 22:428–440CrossRefPubMedGoogle Scholar
  13. 13.
    Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L (2009) ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 135:1369–1376CrossRefPubMedGoogle Scholar
  14. 14.
    Teng L, Nakada M, Zhao SG, Endo Y, Furuyama N, Nambu E, Pyko IV, Hayashi Y, Hamada JI (2011) Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy. Br J Cancer 104:798–807. doi: 10.1038/bjc.2011.12 PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Hefti M, Albert I, Luginbuehl V (2012) Phenytoin reduces 5-aminolevulinic acid-induced protoporphyrin IX accumulation in malignant glioma cells. J Neurooncol 108:443–450. doi: 10.1007/s11060-012-0857-9 CrossRefPubMedGoogle Scholar
  16. 16.
    Lawrence JE, Patel AS, Rovin RA, Belton RJ Jr, Bammert CE, Steele CJ, Winn RJ (2014) Quantification of protoporphyrin IX accumulation in glioblastoma cells: a new technique. ISRN Surg 2014:405360. doi: 10.1155/2014/405360 PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Hochhaus G, Barth J, al-Fayoumi S, Suarez S, Derendorf H, Hochhaus R, Mollmann H (2001) Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate (DP). J Clin Pharmacol 41:425–434CrossRefPubMedGoogle Scholar
  18. 18.
    Lancelin F, Franchon E, Kraoul L, Garciau I, Brovedani S, Tabaouti K, Landre E, Chassoux F, Paubel P, Piketty ML (2007) Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit 29:576–583. doi: 10.1097/FTD.0b013e318157032d CrossRefPubMedGoogle Scholar
  19. 19.
    Schatlo B, Fandino J, Smoll NR, Wetzel O, Remonda L, Marbacher S, Perrig W, Landolt H, Fathi A-R (2015) Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery. Neuro-oncology 12:1560–1567. doi: 10.1093/neuonc/nov049 CrossRefGoogle Scholar
  20. 20.
    Awad AJ, Sloan A (2014) The use of 5-ALA in glioblastoma resection: two cases with long-term progression-free survival. Cureus. doi: 10.7759/cureus.202 Google Scholar
  21. 21.
    Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, Tatagiba M (2014) Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol 40:297–304. doi: 10.1016/j.ejso.2013.11.022 CrossRefPubMedGoogle Scholar
  22. 22.
    Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM (2007) Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67:6882–6888. doi: 10.1158/0008-5472.CAN-06-3948 CrossRefPubMedGoogle Scholar
  23. 23.
    Koc K, Anik I, Cabuk B, Ceylan S (2008) Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 22:99–103. doi: 10.1080/02688690701765524 CrossRefPubMedGoogle Scholar
  24. 24.
    Schucht P, Beck J, Raabe A (2015) Response to: “Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery”. Eur J Surg Oncol 41:604–605. doi: 10.1016/j.ejso.2014.07.044 CrossRefPubMedGoogle Scholar
  25. 25.
    Schwake M, Stummer W, Suero Molina EJ, Wolfer J (2015) Simultaneous fluorescein sodium and 5-ALA in fluorescence-guided glioma surgery. Acta Neurochir (Wien) 157:877–879. doi: 10.1007/s00701-015-2401-0 CrossRefGoogle Scholar
  26. 26.
    Yamada S, Muragaki Y, Maruyama T, Komori T, Okada Y (2015) Role of neurochemical navigation with 5-aminolevulinic acid during intraoperative MRI-guided resection of intracranial malignant gliomas. Clin Neurol Neurosurg 130:134–139. doi: 10.1016/j.clineuro.2015.01.005 CrossRefPubMedGoogle Scholar
  27. 27.
    Stummer W, Beck T, Beyer W, Mehrkens JH, Obermeier A, Etminan N, Stepp H, Tonn JC, Baumgartner R, Herms J, Kreth FW (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurooncol 87:103–109. doi: 10.1007/s11060-007-9497-x CrossRefPubMedGoogle Scholar
  28. 28.
    Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM (1997) 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79:2282–2308CrossRefPubMedGoogle Scholar
  29. 29.
    Kim JE, Cho HR, Xu WJ, Kim JY, Kim SK, Kim SK, Park SH, Kim H, Lee SH, Choi SH, Park S, Park CK (2015) Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. OncotargetGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Johnathan E. Lawrence
    • 1
  • Christopher J. Steele
    • 2
  • Richard A. Rovin
    • 3
  • Robert J. BeltonJr.
    • 1
  • Robert J. Winn
    • 1
  1. 1.Upper Michigan Brain Tumor CenterNorthern Michigan UniversityMarquetteUSA
  2. 2.College of Human MedicineMichigan State UniversityLansingUSA
  3. 3.Aurora Neuroscience Innovation InstituteAurora Health CareMilwaukeeUSA

Personalised recommendations